Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.

• Results Overview

  Lebrikizumab was effective at treating moderate-to-severe eczema over 52 weeks, with similar results whether given every 2 or 4 weeks after the initial 16-week treatment period. The medication was generally safe with most side effects being mild or moderate.

• Study Summary

  Num Participants:

  None

  Study Type:

  Rct

  Control Group:

  Placebo Every 2 Weeks (After Initial 16 Weeks Of Lebrikizumab)

  Efficacy End Points Treatment:

  {'IGA 0/1 with ≥2 point improvement Q2W': 71.2, 'IGA 0/1 with ≥2 point improvement Q4W': 76.9, 'EASI-75 Q2W': 78.4, 'EASI-75 Q4W': 81.7}

  Efficacy End Points Control:

  {'IGA 0/1 with ≥2 point improvement': 47.9, 'EASI-75': 66.4}

  Side Effects Treatment:

  Adverse Event	Severity	Percentage Affected
  Various Events	Low	93.1

  Side Effects Control:

  Adverse Event	Severity	Percentage Affected